Live Analyst Rating Changes 1505 upgrades, downgrades & price-target moves · freshest Wall Street data, updated daily View live feed →
Analyst Tracker/Mason Carrico
STEP
Mason Carrico
Stephens
Wall Street Analyst
★★☆☆☆
#1857
on 13Foresight · ranked by our own returns
57%
Success Rate
-4.6%
Average Return
8 of 14 calls profitable · -20.9% vs benchmark
🔒 5-year track record is Pro. Showing 1-year — upgrade.
📈 Across the calls we could measure, roughly 57% of Mason Carrico's ratings turned a profit when each position was held for 1 year — averaging -4.6% per rating. These figures are computed by 13Foresight from historical prices, not supplied by the analyst.

Rating Distribution

7 Buy 2 Hold 0 Sell
Mason's Stock Coverage 15 ratings · 2026-06-18
Company Date Position Consensus ⓘ Price Target ⓘ 1-Yr Return
CTKB
Cytek Biosciences
 May 13, 2026 BUY Buy
+45.1% avg upside
5 analysts
$4.75
19.25% Upside
 +13.9%
ESTA
Establishment Labs Holdings
 Feb 25, 2026 BUY Strong Buy
+0.0% avg upside
12 analysts
$90.00
9.19% Upside
 +5.5%
GKOS
Glaukos
 Jan 02, 2026 BUY Strong Buy
+7.8% avg upside
20 analysts
$145.00
13.79% Upside
 +30.1%
PACB
Pacific Biosciences
 Nov 10, 2025 BUY Buy
+225.5% avg upside
14 analysts
$2.00
49.26% Upside
 -36.4%
NEO
NeoGenomics
 Sep 02, 2025 BUY Strong Buy
+46.6% avg upside
17 analysts
$11.00
5.97% Upside
 +26.6%
ILMN
Illumina
 Aug 04, 2025 BUY Buy
-9.2% avg upside
30 analysts
$110.00
30.77% Downside
 +61.6%
PRCT
PROCEPT BioRobotics
 Jul 09, 2025 BUY Buy
+85.2% avg upside
16 analysts
$70.00
234.68% Upside
 -61.8%
MYGN
Myriad Genetics
 Oct 11, 2024 HOLD Hold
+326.2% avg upside
24 analysts
$30.00
584.96% Upside
 -68.8%
CDNA
CareDx
 May 13, 2024 BUY Buy
+36.9% avg upside
16 analysts
$18.00
23.31% Downside
 +7.7%
TXG
10x Genomics
 May 18, 2023 BUY Buy
-24.1% avg upside
18 analysts
$65.00
102.21% Upside
 -54.5%
CSTL
Castle Biosciences
 May 08, 2023 BUY Strong Buy
+102.6% avg upside
9 analysts
$41.00
102.41% Upside
 +4.0%
GH
Guardant Health
 Feb 16, 2023 BUY Strong Buy
-5.0% avg upside
30 analysts
$63.00
51.13% Downside
 -21.9%
NTRA
Natera
 Dec 16, 2022 BUY Strong Buy
+9.1% avg upside
26 analysts
 — +36.2%
VCYT
Veracyte
 Dec 05, 2022 BUY Strong Buy
-18.0% avg upside
17 analysts
$32.00
37.56% Downside
 -6.6%
IMDX
Insight Molecular Diagnostics
 May 24, 2022 HOLD Buy
+1.1% avg upside
10 analysts
$1.25
76.57% Downside
 ·
🔒 10 more ratings — with price targets, crowd consensus and our measured returns.
Sign in free to unlock See Pro plans
Free account unlocks every analyst's full coverage table.
Mason Carrico — Frequently Asked Questions
How accurate are Mason Carrico's stock ratings?
Based on the calls 13Foresight could measure, about 57% of Mason's ratings were profitable over a one-year hold, with an average return of -4.6% per rating, or -20.9% versus the S&P 500. We score every analyst the same way, from historical prices.
How is Mason ranked on 13Foresight?
Mason Carrico is currently ranked #1857 with a 2-star rating. Our rank blends hit rate, average return versus the market, and how many calls we have to judge — so a long, consistent record outweighs a few lucky picks. It is our own calculation, updated daily.
Which stocks does Mason cover?
Mason most recently has ratings on CTKB, ESTA, GKOS, PACB, NEO, ILMN, PRCT, MYGN, CDNA, TXG, CSTL, GH and 3 more. See the full coverage table above for positions, price targets and our measured returns.
Where can I see other analyst ratings?
Browse the full analyst leaderboard to compare Wall Street analysts ranked by their measured performance, success rate and average return.

Disclaimer: 13Foresight compiles analyst ratings and price targets from publicly available sources. Performance metrics, rankings and star ratings shown here are calculated independently by 13Foresight from historical market prices and may differ from figures published elsewhere. This information may be incomplete, delayed or inaccurate, is provided for research and informational purposes only, and is not investment advice. The underlying ratings and opinions are those of the respective analysts and their firms; 13Foresight accepts no liability for any decisions made based on this data.